U.S. STOCKS ON THE MOVE-Costco, FedEx, U.S. metal miners, Nike
Trevi Therapeutics steadies after pricing $55 mln stock offering
Advisory: Alert on Trevi Therapeutics pricing withdrawn
Brief: Trevi Therapeutics Announces Pricing Of $55 Mln Public Offering
Brief: Trevi Therapeutics Announces Proposed Public Offering
U.S. STOCKS ON THE MOVE-Rumble Inc, Virios Therapeutics, KnowBe4
U.S. STOCKS ON THE MOVE-Take-Two, Virios Therapeutics, Netflix
Trevi up as lung therapy meets main goal in mid-stage study
Brief: Trevi Therapeutics Announces Positive Data From Full Set Of Subjects In Phase 2 Canal Trial Of Haduvio
Brief: Trevi Therapeutics - Data From Full Set Of Subjects In Completed Phase 2 Canal Trial In Chronic Cough In Ipf Expected In Q3 Of 2022
Trevi Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Trevi Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-EVgo, Microstrategy, Carnival Corp, Apple
U.S. STOCKS ON THE MOVE-2U Inc, General Mills, Tesla, Shopify
U.S. STOCKS ON THE MOVE-Bed Bath & Beyond, Domino's Pizza, Tesla
Trevi Therapeutics up as itch treatment succeeds in study
Brief: Trevi Therapeutics Reports Positive Results From The Ph2b/3 Prism Trial Of Haduvio In The Treatment Of Prurigo Nodularis
Trevi Therapeutics rises as Oppenheimer sees promise in cough, itch treatment
Trevi Therapeutics Inc reports results for the quarter ended in March - Earnings Summary